330
Participants
Start Date
November 30, 2014
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
diepalrestat choline
aldose reductase inhibitor
Placebo
Placebo
Endocrinology Dispensary, Moscow
Morozovskaya Children City Hospital of Moscow, Moscow
I M Sechenov First Moscow State Medical University, Moscow
IM Sechenov First Moscow State Medical University, Moscow
IM Sechenov First Moscow State Medical University, Moscow
City Clinical Hospital No 71, Moscow
Central Clinical Hospital No 1 of JSC Russian Railway, Moscow
City Clinical Hospital No 50, Moscow
The Federal Bureau of Medical and Social Expertise, Moscow
Regional Clinical Hospital, Yaroslavl
NV Solovyov Clinical Emergency Hospital, Yaroslavl
Health Services Severstal, Cherepovets
Northern State Medical University, Arkhangelsk
VA Baranov Respublical Hospital, Petrozavodsk
Imc Sogaz, Saint Petersburg
Medical Center Reavita, Saint Petersburg
City Hospital of the Holy Martyr Elizabeth, Saint Petersburg
City Hospital No 40 of the Kurortny District, Saint Petersburg
Nikolaev Hospital, Saint Petersburg
Rostov State Medical University, Rostov-on-Don
State Medical University, Volgograd
City Polyclinic No 20, Saratov
Central City Clinical Hospital, Ulyanovsk
Bashkir State Medical University, Ufa
Perm State Medical Academy, Perm
Clinic of Neurology, Yekaterinburg
Kemerovo Regional Clinical Hospital, Kemerovo
Lead Sponsor
NeuromaxBionevia
INDUSTRY